Advanced pharmaceutical bulletin最新文献

{"title":"Impact of <i>Elateriospermum tapos</i> Supplementation on Leptin and Hypothalamic Signaling in Female Offspring of High-Fat Diet-Induced Obese.","authors":"Santhra Segaran Balan, Hasnah Bahari, Azrina Zainal Abidin, Nurul Husna Shafie, Maizaton Atmadini Abdullah, Azmiza Syawani Jasni","doi":"10.34172/apb.43919","DOIUrl":"10.34172/apb.43919","url":null,"abstract":"<p><strong>Purpose: </strong>The central nervous system plays a crucial role in regulating food intake and energy expenditure to maintain energy homeostasis in the body. With rising obesity rates, alternative therapeutic strategies, including herbal-based interventions, are gaining attention. <i>Elateriospermum tapos</i> a plant that rich in flavonoids, has shown potential supporting weight reduction. This study aimed to evaluate the effects of <i>E. tapos</i> seed and shell supplementation on the hypothalamic feeding pathway in obese female rats and their offspring.</p><p><strong>Methods: </strong>Thirty adult female Sprague-Dawley rats were used in this study. Obesity was induced in 24 rats via high-fat diet (HFD) for five weeks. Six rats were maintained on a normal diet as the control group (DCG). The obese rats were then divided into four groups: negative control (DNG, HFD only), positive control (DPG, HFD+orlistat 200 mg/kg), treatment 1 (DTX1, HFD+<i>E. tapos</i> seed 200 mg/kg), and treatment 2 (DTX2, HFD+<i>E. tapos</i> shell 200 mg/kg). Treatments were administered daily for six weeks before mating. On postnatal day 21 (PND21), blood and hypothalamus samples were collected from female rats and their female offspring. Plasma leptin levels were measured using ELISA, and expression of leptin receptor (Obr), proopiomelanocortin (POMC), and neuropeptide Y (NPY) in the hypothalamus was assessed by western blotting.</p><p><strong>Results: </strong>DTX2 and offspring (OTX2) groups showed significantly (<i>P</i><0.05) lower levels of leptin. Western blot results indicate Obr, POMC and NPY protein significantly (<i>P</i><0.05) higher expression in DNG and ONG compared to the other groups.</p><p><strong>Conclusion: </strong>In conclusion, the <i>E. tapos</i> shell significantly reduced maternal obesity in female offspring at PND21 compared to its seed.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"186-193"},"PeriodicalIF":3.1,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gouty Arthritis Treatment: Advancements in Topical Lipid-Based Nanocarrier Delivery Systems.","authors":"Shubham Kumar, Shreya Kaul, Neha Jain, Chirag Jain, Manisha Pandey","doi":"10.34172/apb.44012","DOIUrl":"10.34172/apb.44012","url":null,"abstract":"<p><p>The formation of urate crystals in the joints causes severe, erratic flare-ups of joint pain, swelling, and erythema in gout, one kind of inflammatory arthritis. The standard treatment currently available involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, allopurinol, febuxostat, and corticosteroids which require lifelong management via oral or parenteral route. The challenge is the therapy adherence as the symptoms become better, patients may quit taking them, which could result in more episodes. In addition, conventional therapy regimes demonstrate insufficient effectiveness and minimal safety owing to these drug molecule's biopharmaceutical limitations, including inadequate chemical stability and an insufficient capacity to target the pathophysiological pathways. Therefore, developing an alternative drug carrier system that can meet the challenge is necessary. In recent years, the use of lipid-based nanocarriers has increased due to their properties of enhancing solubility and bioavailability of poor-soluble drugs, site-specific targeting, and sustained release. In this review, an attempt has been made to highlight the challenges of available therapies for gout along with its pathophysiology, the mechanism of lipoidal nanocarriers permeation via topical route, and recent advancements in gout therapy using lipid nanocarriers based on preclinical experiments. In addition, patents and clinical trials of lipid-based nanocarriers have also been discussed. Lipid-based nanocarriers present a potential strategy specifically for topical gout therapy as this can offer localized therapy with minimal systemic exposure. Even though lipid-based nanocarriers show promise for gout topical therapy, several issues that need to be looked after, including economically viable scalability and regulatory approvals.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"11-26"},"PeriodicalIF":3.1,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.","authors":"ArunSundar MohanaSundaram, Velmurugan Raja, Yeshwanth Kamalakannan, Md Aminul Islam","doi":"10.34172/apb.43870","DOIUrl":"10.34172/apb.43870","url":null,"abstract":"","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"4-6"},"PeriodicalIF":3.1,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosome-Like Nanoparticles from Indonesian Red and Emprit Ginger Varieties Suppress LPS-Induced IL-6 Production in RAW 264.7 Macrophages.","authors":"Daisy Ramadhani Muhammad, Natasya Emmanuela, Iriawati Iriawati, Christofora Hanny Wijaya, Ika Dewi Ana, Triarti Dewi Kencana Wungu, Diah Ratnadewi, Hiroshi Takemori, Anggraini Barlian","doi":"10.34172/apb.42675","DOIUrl":"10.34172/apb.42675","url":null,"abstract":"<p><strong>Purpose: </strong>Studies have shown the potential of exosomes as therapeutic agents with anti-inflammatory properties. However, the clinical application of mammalian-derived exosomes is hindered by mass production challenges and strict regulations. Plant-derived exosome-like nanoparticles (PELNs) are a more economical alternative possessing a similar therapeutic potential. Ginger is a readily available plant with components that are clinically proven to inhibit inflammation. Therefore, it is interesting to investigate the potential of red ginger and emprit ginger, cultivated varieties in Indonesia possessing the most potent anti-inflammatory activities, as a PELN source for anti-inflammatory therapy.</p><p><strong>Methods: </strong>In this work, PELNs from the rhizomes of red ginger (RG-ELN) and emprit ginger (EG-ELN) were obtained through differential centrifugation and polymer precipitation using PEG6000. The PELNs were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), and bicinchoninic acid assay. Their internalization and effect on RAW 246.7 cell viability were also assessed. The anti-inflammatory potential of PELNs was investigated by assessing interleukin 6 (IL-6) expression of lipopolysaccharide (LPS)-stimulated macrophages treated with RG-ELN and EG-ELN.</p><p><strong>Results: </strong>Both RG-ELN and EG-ELN exhibited cup-shaped morphologies with average sizes of 195.83±1.35 and 194.40±8.40 nm, respectively. Both PELNs can be internalized within 2 h and did not significantly affect RAW 264.7 cell viability after 24 h. The reverse transcription quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay results indicated a significantly lower expression and secretion of IL-6 in the macrophage cells pre-treated with RG-ELN and EG-ELN.</p><p><strong>Conclusion: </strong>The RG-ELN and EG-ELN samples were successfully obtained through the polymer precipitation method, as confirmed by the TEM and DLS results which aligned with typical PELN characteristics. The pre-treatment of RG-ELN and EG-ELN to activated RAW 264.7 cells decreased the pro-inflammatory cytokine IL-6 expression relative to activated controls.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"60-69"},"PeriodicalIF":3.1,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small T Oncoprotein of Merkel Cell Polyomavirus Attenuates Cisplatin-Induced Apoptosis and Enhances E1, E6/E7, MMP-1, and Ki-67 Expression in HeLa Cervical Cancer Cells.","authors":"Fatemeh Pakdel, Seyed Masoud Hosseini, Neda Soleimani, Ali Farhadi","doi":"10.34172/apb.43882","DOIUrl":"10.34172/apb.43882","url":null,"abstract":"<p><strong>Purpose: </strong>Cervical cancer (CxCa) is primarily caused by high-risk human papillomaviruses (hrHPV), which disrupt p53 and pRb regulation, leading to uncontrolled growth and progression. Co-infection with polyomaviruses like MCPyV in some HPV-positive cases suggests a potential combined effect on tumor development. Cisplatin is commonly used for advanced CxCa, but resistance remains a challenge. This study examines whether MCPyV sT oncoprotein and HPV-18 oncoproteins affect key gene transcription, influencing proliferation and cisplatin resistance in CxCa.</p><p><strong>Methods: </strong>The sT gene was cloned into the pCMV6 vector, and HeLa cells were transfected with pCMV6-sT using Lipofectamine 3000. Transfection efficiency was assessed via fluorescence microscopy and flow cytometry. Protein expression was analyzed using SDS-PAGE and Western blotting. Cytotoxicity was measured with the MTT assay, gene expression was analyzed by RT-qPCR, Ki-67 staining was performed on cell blocks, and cisplatin-induced effects on proliferation and apoptosis were examined.</p><p><strong>Results: </strong>Cytotoxicity assays showed a significant increase in cell viability at 0.2 μg of sT plasmid after 72 hours (13.76%, <i>P</i><0.05). MCPyV sT expression significantly upregulated E1 (4.22-fold), E6/E7 (3.80-fold), and MMP1 (6-fold) mRNA levels (<i>P</i><0.001). Increased Ki-67 positivity indicated enhanced proliferation. Additionally, sT expression reduced cisplatin-induced apoptosis, with fewer apoptotic cells observed in the sT+cisplatin group than in the cisplatin-only group (25.9% vs. 38.3%, <i>P</i><0.05).</p><p><strong>Conclusion: </strong>The presence of MCPyV sT and HPV oncoproteins together enhances resistance to cisplatin-induced apoptosis in CxCa cells, highlighting the need for further investigation into viral oncoprotein interactions to overcome therapeutic resistance.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"194-205"},"PeriodicalIF":3.1,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Well-regulated Dermal Regeneration Using Amnion-containing Scaffold in a Preclinical Study.","authors":"Masumeh Staji, Arezoo Karamivandishi, Roya Fattahi, Masoud Soleimani, Hamidreza Moosavian, Simzar Hosseinzadeh","doi":"10.34172/apb.43476","DOIUrl":"10.34172/apb.43476","url":null,"abstract":"<p><strong>Purpose: </strong>we investigated the synergistic influence of amnion and keratinocytes on dermal regeneration in mice.</p><p><strong>Methods: </strong>A scaffold derived from amnion and gelatin via electrospinning was used to synthesize a polyurethane-based scaffold. polyurethane/gelatin/amnion (PU/G/A) scaffold was characterized by scanning electron microscopy (SEM), FTIR, and tensile test. biocompatibility of the corresponding scaffold was investigated using the MTT method in the culture of keratinocytes.</p><p><strong>Results: </strong>The SEM images showed sufficient cell adhesion on the PU/G/A scaffold. The tensile test results indicated that the scaffold containing PU/G/A with the lowest Young's modulus (12 MPa±2.1) displayed higher elasticity than the scaffold without amnion. Furthermore, the MTT assay revealed that the amniotic scaffold contributed to 100% cell viability (<i>P</i>≤0.0001 compared to control) and proliferation. Moreover, an in vivo study conducted on mice showed that the PU/G/A/ keratinocytes scaffold results in increased granulation, tissue formation and wound closure (<i>P</i><0.001 compared to control).</p><p><strong>Conclusion: </strong>This innovative nanofiber device not only addresses the limitations of traditional dressings but also offers additional functionalities such as wound compatibility, gas exchange, promotion of angiogenesis in the injured area and a substrate that amplifies the biological functions of stem cells.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"206-216"},"PeriodicalIF":3.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation and Anti-cancer Evaluation of Methotrexate-loaded Inositol-6 Phosphate Cross-linked Chitosan Nanoparticles on Breast Cancer.","authors":"Masoud Farshbaf, Nasrin Gobakhlou, Muhammad Sarfraz, Javid Shahbazi-Mojarrad, Mohammad Feyzizadeh, Hamed Hamishehkar, Parvin Zakeri-Milani, Hadi Valizadeh","doi":"10.34172/apb.43661","DOIUrl":"10.34172/apb.43661","url":null,"abstract":"<p><strong>Purpose: </strong>Chitosan nanoparticles (CNs) have directed considerable research efforts towards developing biocompatible, biodegradable, inexpensive and efficient particulate drug delivery systems.</p><p><strong>Methods: </strong>In the present investigation, we utilized green and safe inositol hexaphosphate (InsP6) as a physical cross-linker to obtain CNs (^InsP6CNs) and compared their size, zeta potential and cell uptake ability with the CNs cross-linked with tripolyphosphate (TPP) as a commonly used cross-linker (^TPPCNs). Methotrexate (MTX) as the model drug was physically incorporated within the both types of CNs (^InsP6CNs_MTX and ^TPPCNs_MTX) and their time-dependent anti-cancer behavior was evaluated on MCF-7 cell line.</p><p><strong>Results: </strong>Compared to ^TPPCNs, ^InsP6CNs were bigger in hydrodynamic diameter and showed far different zeta potential value. The MTX encapsulation efficiency was much higher for ^InsP6CNs_MTX than that of ^TPPCNs_MTX. ^InsP6CNs and ^TPPCNs showed similar <i>in vitro</i> cell uptake behavior, examined on MCF-7 cell line. Furthermore, after 24 h, ^InsP6CNs_MTX had the most <i>in vitro</i> antitumor effect on the MCF-7 cells, compared to free MTX and ^TPPCNs_MTX.</p><p><strong>Conclusion: </strong>Consequently, InsP6 can be presented as an accessible and cost-effective member of physical cross-linkers to prepare efficient CNs as drug delivery systems.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"217-222"},"PeriodicalIF":3.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanovaccines against Cervical Cancer: Reliable Strategies to Circumvent Limitations of Traditional Therapeutic Vaccines.","authors":"Enwa Felix Oghenemaro, Safia Obaidur Rab, Ebraheem Abdu Musad Saleh, Asmaa F Kassem, Jasur Rizaev, Deepak Nathiya, Parjinder Kaur, M Ravi Kumar, Karam Kadhim, Ahmed M Hashim","doi":"10.34172/apb.43712","DOIUrl":"10.34172/apb.43712","url":null,"abstract":"<p><p>Cervical cancer ranks fourth in terms of diagnosis and cancer-related deaths in women worldwide. Despite the approval of prophylactic vaccines against cervical cancers, these vaccines are not able to eradicate the existing ones. Therefore, various platforms have been developed to design therapeutic vaccines against cervical cancers, including DNA/RNA-based, protein/peptide-based, vector-based, and cell-based platforms. Despite the advantages of each platform, therapeutic vaccines have displayed limited clinical benefit in patients with cervical cancer, which is partially associated with inefficient delivery of vaccine components. To address these issues, different nanoplatforms have been developed to carry cellular or molecular components of vaccines to target cells and lymphoid tissues, thus promoting the durability and potency of immune responses against tumor cells and antigens besides decreasing side effects. Moreover, nanoparticles (NPs), as adjuvants and/or carriers, provide other advantages, including sufficient antigen loading and uptake by antigen-presenting cells (APCs), adaptable antigen presentation, high immunogenicity, high stability, increased lymph node retention, and precise targeting. Thus, nanovaccines also lead us to design and develop personalized vaccines against cervical cancer. Here, we discuss platforms that have been used in clinical trials for the treatment of cervical cancer, their advantages and disadvantages, platforms for developing nanovaccines, and how they improve the therapeutic efficacy of vaccines.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"46-59"},"PeriodicalIF":3.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GATA3 and Aging Raise the Susceptibility of Metastasis to High-Grade Serous Ovarian Carcinoma.","authors":"Mohnad Abdalla, Amr Ahmed El-Arabey, Zhongtao Gai","doi":"10.34172/apb.43915","DOIUrl":"10.34172/apb.43915","url":null,"abstract":"","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"1-3"},"PeriodicalIF":3.1,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vemurafenib Induces Senescent Phenotype with Increased Adhesion in BRAF Mutant A375 but not in Wild Type BRAF SK-MEL-2 Melanoma Cells.","authors":"Aleksandra Rashidovna Esimbekova, Vasiliy Dmitrievich Belenyuk, Andrey Anatolievich Savchenko, Tatiana Gennadievna Ruksha","doi":"10.34172/apb.42808","DOIUrl":"10.34172/apb.42808","url":null,"abstract":"<p><strong>Purpose: </strong>The present study aimed to determine the selective effects of BRAF V600E inhibitor on focal adhesion in melanoma cells with respect to their phenotypic reprogramming.</p><p><strong>Methods: </strong>Flow cytometry was used to analyse the distribution of BRAFV600E and BRAFWT melanoma cells throughout the cell cycle post-vemurafenib treatment. Senescent cells were identified based on b-galactosidase activity and the mRNA expression of cell cycle proteins, CCND1 and RBL1. Centrifugal cell adhesion assay was used to determine the adhesive capacities of resting and proliferative BRAF mutant and BRAF wild-type melanoma cells under vemurafenib treatment. Fibronectin binding was evaluated by spectrophotometry and quantitative real-time PCR to measure the mRNA levels of integrins: ITGAV, ITGA5, ITGB1 and ITGB3.</p><p><strong>Results: </strong>Vemurafenib increases the proportion of melanoma BRAFV600E-positive cells in the G0 phase of a cell cycle. Melanoma cells entering the G0 phase after vemurafenib treatment indicated an upregulation of senescence-associated markers. Non-proliferating melanoma cell number was elevated among vemurafenib-treated BRAFV600E cells with enhanced attachment. BRAFV600E-positive but not BRAFV600E-negative cells were characterised by upregulated ITGAV.</p><p><strong>Conclusion: </strong>The current results demonstrated that vemurafenib induces the phenotypic switch in melanoma cells depending on their mutational status. It also strengthens the adhesive features of senescent cells, increasing their binding to fibronectin via ITGAV, which may be a part of the phenotypic mode of drug resistance or slow interaction of proliferating cancer cells with the extracellular matrix (ECM). Thus, targeting senescent cells by focal adhesion modulators may be a promising approach to control drug-resistant melanoma cells.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"176-185"},"PeriodicalIF":3.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}